
CLAIMS

1. A compound of Formula (III):



(III),

or a pharmaceutically acceptable salt thereof,

wherein:

R^1 is chosen from absent, hydrogen, C_1-C_6 alkyl groups, C_1-C_6 alkylalkoxy groups, C_1-C_6 alkylamino groups, C_1-C_6 alkylcarboxylic acid groups, C_1-C_6 alkylhydroxy groups, C_3-C_8 cycloalkyl groups, benzyl groups, C_3-C_8 heterocyclyl groups, -O-C(=O)-(C_1-C_6 alkyl) groups, and -CD_3;

R^2 is a linker L comprising at least one cleavable peptide moiety;






R^3 is chosen from hydrogen, C_1-C_6 alkyl groups, C_1-C_6 alkylalkoxy groups, C_1-C_6 alkylamino groups, C_1-C_6 alkylcarboxylic acid groups, C_1-C_6 alkylhydroxy groups, C_3-C_8 cycloalkyl groups, benzyl groups, C_3-C_8 heterocyclyl groups, and -O-C(=O)-(C_1-C_6 alkyl) groups;

R^4, R^5, and R^8 are each independently chosen from hydrogen, hydroxyl groups, -O-(C_1-C_6 alkyl) groups, -O-C(=O)-(C_1-C_6 alkyl) groups, and C_1-C_6 alkyl groups;

R^6 and R^7 are each independently chosen from hydrogen, -O-R^{17}, -O-C(=O)-R^{17}, -O-C(=O)-$NR^{15}R^{16}$, C_1-C_6 alkyl groups, and -$NR^{15}R^{16}$;


R^{15} and R^{16} are each independently chosen from hydrogen, R^{17}, -C(=O)-R^{17}, and -C(=O)-O-R^{17};

R^{17} is chosen from hydrogen, C_1-C_6 alkyl groups, C_3-C_8 cycloalkyl groups, benzyl groups, and C_3-C_8 heterocyclyl groups; and

Z'' is chosen from , , , , and ;

wherein R^1, R^3, R^4, R^5, R^6, R^7, R^8, R^{15}, R^{16}, and R^{17} are each independently substituted with 0 to 3 groups independently chosen from halogens, hydroxyl groups, C_1-C_6 alkyl groups, -O-(C_1-C_6 alkyl) groups, -$NR^{15}R^{16}$, C_3-C_8 cycloalkyl groups, C_1-C_6 alkylhydroxy groups, C_1-C_6 alkylalkoxy groups, benzyl groups, and C_3-C_8 heterocyclyl groups;

wherein at least one of R^6 and R^7 is hydrogen; and

wherein if Z'' is  and R^3, R^6, and R^7 are H and R^4 is methoxy and R^5 is hydroxyl, then R^1 is neither absent nor methyl.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein:

R^1 is chosen from absent, hydrogen, C_1-C_4 alkyl groups, C_1-C_4 alkylcarboxylic acid groups, C_1-C_4 alkylhydroxy groups, and C_3-C_8 cycloalkyl groups;

R^2 is a linker L comprising at least one cleavable peptide moiety;

R^3 is chosen from hydrogen, C_1-C_4 alkyl groups, C_1-C_4 alkylalkoxy groups, C_1-C_4 alkylcarboxylic acid groups, and C_1-C_4 alkylhydroxy groups;

R^4 is chosen from hydrogen, hydroxyl groups, -O-(C_1-C_4 alkyl) groups, -O-C(=O)-(C_1-C_4 alkyl) groups, and C_1-C_4 alkyl groups;

R^5 is chosen from hydrogen, hydroxyl groups, -O-(C_1-C_4 alkyl) groups, and C_1-C_4 alkyl groups;






R^6 is chosen from hydrogen, -O-R^{17}, -O-C(=O)-R^{17}, and C_1-C_4 alkyl groups~~, and a linker~~;

R^7 is chosen from hydrogen, -O-R^{17}, -O-C(=O)-R^{17}, -O-C(=O)-$NR^{15}R^{16}$, C_1-C_6 alkyl groups, and -$NR^{15}R^{16}$;

R^8 is chosen from hydrogen, hydroxyl groups, -O-(C_1-C_4 alkyl) groups, and C_1-C_4 alkyl groups;


R^{15} and R^{16} are each independently chosen from hydrogen, R^{17}, -C(=O)-R^{17}, and -C(=O)-O-R^{17};

R^{17} is chosen from hydrogen, C_1-C_6 alkyl groups, C_3-C_8 cycloalkyl groups, benzyl groups, and C_3-C_8 heterocyclyl groups;

Z'' is chosen from , , , , and ;

wherein R^1, R^3, R^4, R^5, R^6, R^7, R^8, R^{15}, R^{16}, and R^{17} are each independently substituted with 0 to 3 groups independently chosen from halogens, hydroxyl groups, C_1-C_6 alkyl groups, -O-(C_1-C_6 alkyl) groups, -$NR^{15}R^{16}$, C_3-C_8 cycloalkyl groups, C_1-C_6 alkylhydroxy groups, C_1-C_6 alkylalkoxy groups, benzyl groups, and C_3-C_8 heterocyclyl groups;

wherein at least one of R^6 and R^7 is hydrogen; and

wherein if Z'' is  and R^3, R^6, and R^7 are H and R^4 is methoxy and R^5 is hydroxyl, then R^1 is neither absent nor methyl.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein:

R^1 is chosen from absent, hydrogen, methyl, and C_1-C_4 alkylcarboxylic acid groups;

R^2 is a linker L comprising at least one cleavable peptide moiety;

R^3 is chosen from hydrogen and C_1-C_4 alkylcarboxylic acid groups;


R^4 is chosen from hydrogen, hydroxyl groups, -O-(C_1-C_4 alkyl) groups, -O-C(=O)-(C_1-C_4 alkyl) groups, and C_1-C_4 alkyl groups;

R^5 is chosen from hydrogen and hydroxyl groups;

R^6 is hydrogen;

R^7 is hydrogen;


R^8 is chosen from hydrogen and hydroxyl groups; and

Z'' is chosen from  ;

wherein R^1, R^3, R^4, R^5, R^6, R^7, R^8 are each independently substituted with 0 to 3 groups independently chosen from halogens, hydroxyl groups, C_1-C_6 alkyl groups, -O-(C_1-C_6 alkyl) groups, C_3-C_8 cycloalkyl groups, C_1-C_6 alkylhydroxy groups, C_1-C_6 alkylalkoxy groups, benzyl groups, and C_3-C_8 heterocyclyl groups; and


wherein if R^3, R^6, and R^7 are H and R^4 is methoxy and R_5 is hydroxyl, then R^1 is neither absent nor methyl.

4. The compound of claim 1, wherein the compound is chosen from a compound of formula

 and


pharmaceutically acceptable salts thereof.

5. The compound of claim 1, wherein the compound is chosen from a compound of formula

 and


pharmaceutically acceptable salts thereof.

6. The compound of claim 1, wherein the compound is chosen from a compound of formula



and pharmaceutically acceptable salts thereof.

7. The compound of claim 1, wherein the compound is chosen from a compound of formula



and pharmaceutically acceptable salts thereof.

8. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


9. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a subject having or suspected of having a neoplastic disorder, comprising a therapeutically effective amount of the compound to be administered to the subject.

10. The use of the compound of claim 9, wherein the neoplastic disorder is a leukemia, a lymphoma, or a myeloma.

11. The use of the compound of claim 10, wherein the myeloma is multiple myeloma.

12. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for reducing or inhibiting growth of a tumor in a subject having or suspected of having a neoplastic disorder, comprising a therapeutically effective amount of the compound to be administered to the subject.


13. The compound of claim 1, wherein the compound is chosen from a compound of formula



and

pharmaceutically acceptable salts thereof.

14. The compound of claim 1, wherein the compound is chosen from a compound of formula



and

pharmaceutically acceptable salts thereof.

15. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the linker L comprising at least one cleavable peptide moiety further comprises at least one spacer unit.

16. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the at least one cleavable peptide moiety comprises valine-alanine (Val-Ala).


17. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the at least one cleavable peptide moiety comprises valine-citrulline (Val-Cit), glutamic acid-valine-citrulline (Glu-Val-Cit), or alanine-alanine-asparagine (Ala-Ala-Asn).

18. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the linker L comprising at least one cleavable peptide moiety comprises p-aminobenzyloxycarbonyl.

19. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the linker L comprising at least one cleavable peptide moiety further comprises a polyethylene glycol moiety and/or an alkyl moiety.


20. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the linker L comprising at least one cleavable peptide moiety further comprises maleimidocaproyl (MC).

21. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the linker L comprising at least one cleavable peptide moiety is a compound of formula:




.

22. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the linker L comprising at least one cleavable peptide moiety is a compound of formula:



23. A compound of formula:



or

a pharmaceutically acceptable salt thereof,

wherein:

R^1 is chosen from absent, hydrogen, C_1-C_6 alkyl groups, C_1-C_6 alkylalkoxy groups, C_1-C_6 alkylamino groups, C_1-C_6 alkylcarboxylic acid groups, C_1-C_6 alkylhydroxy groups, C_3-C_8 cycloalkyl groups, benzyl groups, C_3-C_8 heterocyclyl groups, -O-C(=O)-(C_1-C_6 alkyl) groups, and -CD_3;

R^2 is a linker L comprising at least one cleavable peptide moiety;

R^3 is chosen from hydrogen, C_1-C_6 alkyl groups, C_1-C_6 alkylalkoxy groups, C_1-C_6 alkylamino groups, C_1-C_6 alkylcarboxylic acid groups, C_1-C_6 alkylhydroxy groups, C_3-C_8 cycloalkyl groups, benzyl groups, C_3-C_8 heterocyclyl groups, and -O-C(=O)-(C_1-C_6 alkyl) groups;






R^4 is chosen from hydrogen, hydroxyl groups, -O-C(=O)-(C_1-C_6 alkyl) groups, and C_1-C_6 alkyl groups;

R^5 and R^8 are each independently chosen from hydrogen, hydroxyl groups, -O-(C_1-C_6 alkyl) groups, -O-C(=O)-(C_1-C_6 alkyl) groups, and C_1-C_6 alkyl groups;

R^6 and R^7 are each independently chosen from hydrogen, -O-R^{17}, -O-C(=O)-R^{17}, -O-C(=O)-$NR^{15}R^{16}$, C_1-C_6 alkyl groups, and -$NR^{15}R^{16}$;

R^{15} and R^{16} are each independently chosen from hydrogen, R^{17}, -C(=O)-R^{17}, and -C(=O)-O-R^{17};

R^{17} is chosen from hydrogen, C_1-C_6 alkyl groups, C_3-C_8 cycloalkyl groups, benzyl groups, and C_3-C_8 heterocyclyl groups; and

Z'' is chosen from , , , , and ;

wherein R^1, R^3, R^4, R^5, R^6, R^7, R^8, R^{15}, R^{16}, and R^{17} are each independently substituted with 0 to 3 groups independently chosen from halogens, hydroxyl groups, C_1-C_6 alkyl groups, -O-(C_1-C_6 alkyl) groups, -$NR^{15}R^{16}$, C_3-C_8 cycloalkyl groups, C_1-C_6 alkylhydroxy groups, C_1-C_6 alkylalkoxy groups, benzyl groups, and C_3-C_8 heterocyclyl groups;

wherein at least one of R^6 and R^7 is hydrogen.